{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:10:50Z","timestamp":1790079050414,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006090","name":"Center for Global Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40258-018-0397-3","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T01:11:12Z","timestamp":1528074672000},"page":"537-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert\u00ae MTB\/RIF for People Living with HIV\/AIDS and People with Presumptive Multidrug-resistant Tuberculosis"],"prefix":"10.1007","volume":"16","author":[{"given":"Sarah Wood","family":"Pallas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Courey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chhaily","family":"Hy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wm. Perry","family":"Killam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"key":"397_CR1","volume-title":"Global Tuberculosis Report 2014","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Global Tuberculosis Report 2014. Geneva: World Health Organization; 2014."},{"key":"397_CR2","volume-title":"Rapid implementation of the Xpert MTB\/RIF diagnostic test: Technical and operational \u2018How to\u2019 practical considerations","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Rapid implementation of the Xpert MTB\/RIF diagnostic test: Technical and operational \u2018How to\u2019 practical considerations. Geneva: World Health Organization; 2011."},{"key":"397_CR3","volume-title":"Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF system: policy statement","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF system: policy statement. Geneva: World Health Organization; 2011."},{"issue":"6","key":"397_CR4","first-page":"16","volume":"134","author":"C Padmapriyadarsini","year":"2011","unstructured":"Padmapriyadarsini C, Narendran G, Swaminathan S. Diagnosis and treatment of tuberculosis in HIV co-infected patients. Indian J Med Research. 2011;134(6):16.","journal-title":"Indian J Med Research"},{"key":"397_CR5","volume-title":"Tuberculosis diagnostics Xpert MTB\/RIF test Fact Sheet","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Tuberculosis diagnostics Xpert MTB\/RIF test Fact Sheet. Geneva: World Health Organization; 2013."},{"issue":"5","key":"397_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1164\/ajrccm\/148.5.1292","volume":"148","author":"BE Jones","year":"1993","unstructured":"Jones BE, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993;148(5):6.","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"397_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1086\/514546","volume":"25","author":"DC Perlman","year":"1997","unstructured":"Perlman DC, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis. 1997;25(2):5.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"397_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1164\/ajrccm.151.1.7812542","volume":"151","author":"C Whalen","year":"1995","unstructured":"Whalen C, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;151(1):7.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"397_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1164\/rccm.200907-0989OC","volume":"181","author":"NR Gandhi","year":"2010","unstructured":"Gandhi NR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181(1):7.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"397_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.9745\/GHSP-D-12-00004","volume":"1","author":"A Piatek","year":"2013","unstructured":"Piatek A, et al. GeneXpert for TB diagnosis: planned and purposeful implementation. Glob Health Sci Pract. 2013;1(1):6.","journal-title":"Glob Health Sci Pract"},{"key":"397_CR11","volume-title":"Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update.","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. Geneva: World Health Organization; 2013."},{"issue":"9776","key":"397_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0140-6736(11)60438-8","volume":"377","author":"CC Boehme","year":"2011","unstructured":"Boehme CC, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert\u00ae MTB\/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):11.","journal-title":"Lancet"},{"issue":"11","key":"397_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0907847","volume":"363","author":"CC Boehme","year":"2010","unstructured":"Boehme CC, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):11.","journal-title":"N Engl J Med"},{"issue":"9","key":"397_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2217\/fmb.11.84","volume":"6","author":"SD Lawn","year":"2011","unstructured":"Lawn SD, Nicol MP. Xpert\u00ae MTB\/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiology. 2011;6(9):16.","journal-title":"Future Microbiology"},{"key":"397_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1371\/journal.pone.0044626","volume":"7","author":"G Carriquiry","year":"2012","unstructured":"Carriquiry G, et al. A diagnostic accuracy study of Xpert\u00ae (R) MTB\/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in lima. Peru. PLoS ONE. 2012;7:9.","journal-title":"PLoS ONE."},{"issue":"6","key":"397_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jinf.2012.02.012","volume":"64","author":"K Chang","year":"2012","unstructured":"Chang K, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert\u00ae MTB\/RIF assay: a meta-analysis. J Infect. 2012;64(6):9.","journal-title":"J Infect"},{"key":"397_CR17","first-page":"11","volume":"7","author":"C Yoon","year":"2012","unstructured":"Yoon C, et al. Impact of Xpert\u00ae MTB\/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS ONE. 2012;7:11.","journal-title":"PLoS ONE"},{"issue":"11","key":"397_CR18","doi-asserted-by":"publisher","first-page":"e1001120","DOI":"10.1371\/journal.pmed.1001120","volume":"8","author":"A Vassall","year":"2011","unstructured":"Vassall A, et al. Rapid diagnosis of tuberculosis with the Xpert MTB\/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011;8(11):e1001120.","journal-title":"PLoS Med"},{"issue":"8","key":"397_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/QAD.0b013e3283522d47","volume":"26","author":"JR Andrews","year":"2012","unstructured":"Andrews JR, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB\/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS. 2012;26(8):987\u201395.","journal-title":"AIDS"},{"issue":"11","key":"397_CR20","doi-asserted-by":"publisher","first-page":"e1001347","DOI":"10.1371\/journal.pmed.1001347","volume":"9","author":"N Menzies","year":"2012","unstructured":"Menzies N, et al. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB\/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347.","journal-title":"PLoS Med"},{"issue":"10","key":"397_CR21","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.5588\/ijtld.13.0095","volume":"17","author":"HW Choi","year":"2013","unstructured":"Choi HW, et al. Cost-effectiveness of Xpert\u00ae MTB\/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis. 2013;17(10):1328\u201335.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"397_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1183\/09031936.00147912","volume":"42","author":"A Pantoja","year":"2012","unstructured":"Pantoja A, et al. Xpert MTB\/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J. 2012;42(3):708\u201320.","journal-title":"Eur Respir J"},{"issue":"1","key":"397_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/QAI.0b013e318246538f","volume":"60","author":"TO Abimbola","year":"2012","unstructured":"Abimbola TO, et al. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;60(1):e1\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"397_CR24","volume-title":"The Gap Report","author":"UNAIDS","year":"2014","unstructured":"UNAIDS. The Gap Report. Geneva: Joint United Nations Programme on HIV\/AIDS; 2014."},{"issue":"4","key":"397_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5588\/pha.14.0082","volume":"4","author":"SC Auld","year":"2014","unstructured":"Auld SC, et al. Rollout of Xpert\u00ae MTB\/RIF in northwest Cambodia for the diagnosis of tuberculosis among PLHA. Public Health Action. 2014;4(4):216\u201321.","journal-title":"Public Health Action"},{"key":"397_CR26","volume-title":"Gross Domestic Product Implicit Price Deflator [GDPDEF]. 2018FRED","author":"US Bureau of Economic Analysis","year":"2018","unstructured":"US Bureau of Economic Analysis. Gross Domestic Product Implicit Price Deflator [GDPDEF]. 2018FRED. Louis: Federal Reserve Bank of St; 2018."},{"key":"397_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S1473-3099(06)70578-3","volume":"6","author":"KR Steingart","year":"2006","unstructured":"Steingart KR, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6:570\u201381.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"397_CR28","doi-asserted-by":"publisher","first-page":"e86461","DOI":"10.1371\/journal.pone.0086461","volume":"9","author":"P Smit","year":"2014","unstructured":"Smit P, et al. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS ONE. 2014;9(3):e86461.","journal-title":"PLoS ONE."},{"issue":"3","key":"397_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5588\/ijtld.12.0392","volume":"17","author":"A Van Rie","year":"2013","unstructured":"Van Rie A, et al. Point-of-care Xpert\u00ae MTB\/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis. 2013;17(3):368\u201372.","journal-title":"Int J Tuberc Lung Dis"},{"key":"397_CR30","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/j.1365-3156.2012.03028.x","volume":"17","author":"K Schnippel","year":"2012","unstructured":"Schnippel K, et al. Scaling up Xpert MTB\/RIF technology: the costs of laboratory\u2014vs. clinic-based roll-out in South Africa. Trop Med Int Health. 2012;17:1142\u201351.","journal-title":"Trop Med Int Health"},{"key":"397_CR31","first-page":"40","volume":"12","author":"M Atif","year":"2012","unstructured":"Atif M, et al. Determination of chest X-ray cost using activity based costing approach at Penang General Hospital, Malaysia. Pan Afr Med J. 2012;12:40.","journal-title":"Pan Afr Med J"},{"key":"397_CR32","first-page":"7","volume":"8","author":"Y Pang","year":"2013","unstructured":"Pang Y, et al. Cost-effectiveness comparison of genechip and conventional drug susceptibility test for detecting multidrug-resistant tuberculosis in China. PLoS ONE. 2013;8:7.","journal-title":"PLoS ONE"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-018-0397-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0397-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0397-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:28:01Z","timestamp":1589668081000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-018-0397-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1007\/s40258-018-0397-3","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,4]]},"assertion":[{"value":"4 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by funding provided by the US Agency for International Development and the US Centers for Disease Control and Prevention, in addition to funding from the President\u2019s Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention. The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The US Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA, and the Cambodia National Tuberculosis Control Program (CENAT) determined the study to be a program evaluation and not research involving human subjects, and therefore no IRB approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical review"}},{"value":"Sarah Wood Pallas, Marissa Courey, Chhaily Hy, William Perry Killam, Dora Warren, and Brittany Moore declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}